204 related articles for article (PubMed ID: 17229509)
1. An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model.
Iijima M; Chaki S
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):622-7. PubMed ID: 17229509
[TBL] [Abstract][Full Text] [Related]
2. SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model.
Breuer ME; van Gaalen MM; Wernet W; Claessens SE; Oosting RS; Behl B; Korte SM; Schoemaker H; Gross G; Olivier B; Groenink L
Naunyn Schmiedebergs Arch Pharmacol; 2009 Jan; 379(1):101-6. PubMed ID: 18668225
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat.
Overstreet DH; Griebel G
Pharmacol Biochem Behav; 2005 Sep; 82(1):223-7. PubMed ID: 16181667
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression.
Hodgson RA; Higgins GA; Guthrie DH; Lu SX; Pond AJ; Mullins DE; Guzzi MF; Parker EM; Varty GB
Pharmacol Biochem Behav; 2007 Mar; 86(3):431-40. PubMed ID: 17291571
[TBL] [Abstract][Full Text] [Related]
5. Involvement of vasopressin 3 receptors in chronic psychological stress-induced visceral hyperalgesia in rats.
Bradesi S; Martinez V; Lao L; Larsson H; Mayer EA
Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G302-9. PubMed ID: 19033533
[TBL] [Abstract][Full Text] [Related]
6. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.
Alonso R; Griebel G; Pavone G; Stemmelin J; Le Fur G; Soubrié P
Mol Psychiatry; 2004 Mar; 9(3):278-86, 224. PubMed ID: 14699428
[TBL] [Abstract][Full Text] [Related]
7. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Nakazato A; Kumagai T; Okubo T; Tomisawa K
J Pharmacol Exp Ther; 1999 May; 289(2):926-35. PubMed ID: 10215672
[TBL] [Abstract][Full Text] [Related]
8. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
Nielsen DM
Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
[TBL] [Abstract][Full Text] [Related]
9. The olfactory bulbectomised rat as a model of depression.
Song C; Leonard BE
Neurosci Biobehav Rev; 2005; 29(4-5):627-47. PubMed ID: 15925697
[TBL] [Abstract][Full Text] [Related]
10. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal.
Surget A; Saxe M; Leman S; Ibarguen-Vargas Y; Chalon S; Griebel G; Hen R; Belzung C
Biol Psychiatry; 2008 Aug; 64(4):293-301. PubMed ID: 18406399
[TBL] [Abstract][Full Text] [Related]
11. Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats.
Breuer ME; Groenink L; Oosting RS; Westenberg HG; Olivier B
Biol Psychiatry; 2007 Apr; 61(8):990-5. PubMed ID: 17141743
[TBL] [Abstract][Full Text] [Related]
12. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
Griebel G; Simiand J; Serradeil-Le Gal C; Wagnon J; Pascal M; Scatton B; Maffrand JP; Soubrie P
Proc Natl Acad Sci U S A; 2002 Apr; 99(9):6370-5. PubMed ID: 11959912
[TBL] [Abstract][Full Text] [Related]
13. Enhanced susceptibility to periodontitis in an animal model of depression: reversed by chronic treatment with the anti-depressant tianeptine.
Breivik T; Gundersen Y; Myhrer T; Fonnum F; Osmundsen H; Murison R; Gjermo P; von Hörsten S; Opstad PK
J Clin Periodontol; 2006 Jul; 33(7):469-77. PubMed ID: 16820034
[TBL] [Abstract][Full Text] [Related]
14. An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.
Serradeil-Le Gal C; Wagnon J; Tonnerre B; Roux R; Garcia G; Griebel G; Aulombard A
CNS Drug Rev; 2005; 11(1):53-68. PubMed ID: 15867952
[TBL] [Abstract][Full Text] [Related]
15. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders.
Griebel G; Stemmelin J; Gal CS; Soubrié P
Curr Pharm Des; 2005; 11(12):1549-59. PubMed ID: 15892661
[TBL] [Abstract][Full Text] [Related]
16. The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats.
Shimazaki T; Iijima M; Chaki S
Eur J Pharmacol; 2006 Aug; 543(1-3):63-7. PubMed ID: 16843459
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression.
Overstreet DH; Keeney A; Hogg S
Eur J Pharmacol; 2004 May; 492(2-3):195-201. PubMed ID: 15178365
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant-mediated reversal of abnormal behavior and neurodegeneration in mice following olfactory bulbectomy.
Jarosik J; Legutko B; Unsicker K; von Bohlen Und Halbach O
Exp Neurol; 2007 Mar; 204(1):20-8. PubMed ID: 17059819
[TBL] [Abstract][Full Text] [Related]
19. AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters.
Blanchard RJ; Griebel G; Farrokhi C; Markham C; Yang M; Blanchard DC
Pharmacol Biochem Behav; 2005 Jan; 80(1):189-94. PubMed ID: 15652395
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant-like effects of the delta-opioid receptor agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in an olfactory bulbectomized rat model.
Saitoh A; Yamada M; Yamada M; Takahashi K; Yamaguchi K; Murasawa H; Nakatani A; Tatsumi Y; Hirose N; Kamei J
Brain Res; 2008 May; 1208():160-9. PubMed ID: 18381208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
